Log In
Print this Print this

Jardiance, empagliflozin (BI-10773)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

U.S. - Undisclosed Review (Treat Type II diabetes);
EU - Standard Review (Treat Type II diabetes);
Japan - Standard Review (Treat Type II diabetes)


Eli Lilly and Co.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today